Lactate: a surprising booster for failing hearts?
NCT ID NCT06121323
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how lactate, a natural substance made by the body, affects heart function in 12 people with chronic heart failure. Researchers gave lactate as an infusion and as a drink, then measured changes in blood flow and heart pressure. The goal was to understand if lactate could help the heart work better, but this was a small, early study to gather information, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sodium lactate
- What this could lead to
- If it works, this could point toward new ways to manage heart failure by using lactate to improve heart function.
- What could go wrong
- This is a very small, early-stage study with only 12 participants, so results may not apply to everyone. It is designed to understand basic effects, not to test a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE, SYSTOLIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aarhus University Hospital
Aarhus, Central Jutland, 8200, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single gene infusion rebuild failing hearts?
- Can a phone app replace cardiac rehab? a new trial puts digital heart care to the test
- Virtual heart team aims to close medication gap for veterans with heart failure
- Could thin air help failing hearts? small study cut short
- Gut health breakthrough? probiotic shows promise for heart failure
- New heart failure drug enters first human safety trial